ST1926

ST1926 is a synthetic atypical adamantyl retinoid originally developed by Sigma-Tau. Unlike classical retinoids such as all-trans retinoic acid (ATRA), ST1926 exerts its antineoplastic effects primarily through the induction of DNA damage and subsequent apoptosis, often in a Retinoic Acid Receptor (RAR)-independent manner. It has demonstrated potent activity against various hematological malignancies, including acute myeloid leukemia (AML) and adult T-cell leukemia/lymphoma (ATLL), as well as solid tumors like ovarian and breast cancer. Clinical development of the oral formulation was limited by rapid metabolism via glucuroconjugation, which resulted in low plasma concentrations. Recent research, particularly by Biogem and the American University of Beirut, has focused on nanoparticle-encapsulated formulations to improve the drug's bioavailability and therapeutic efficacy in AML and other resistant cancers.

Other names

(E)-3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acidadamantyl retinoidatypical retinoid ST1926